Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Dec 1;15(23):7361-7.
doi: 10.1158/1078-0432.CCR-09-0761. Epub 2009 Nov 17.

Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas

Elizabeth Fox  1 , Brigitte C Widemann, Douglas S Hawkins, Nalini Jayaprakash, Ramzi Dagher, Alberta A Aikin, Donna Bernstein, Lauren Long, Crystal Mackall, Lee Helman, Seth M Steinberg, Frank M Balis
Affiliations
Randomized Controlled Trial

Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas

Elizabeth Fox et al. Clin Cancer Res. .

Abstract

Purpose: To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy.

Experimental design: Patients were randomized to receive a single dose of 100 mcg/kg of pegfilgrastim s.c. or 5 mcg/kg/day of filgrastim s.c., daily until neutrophil recovery after two treatment cycles with vincristine, doxorubicin, and cyclophosphamide (VDC) and two cycles of etoposide and ifosfamide (IE). The duration of severe neutropenia (absolute neutrophil count, < or =500/mcL) during cycles 1 to 4 and cycle duration for all cycles were compared. Pharmacokinetics of pegfilgrastim and filgrastim and CD34+ stem cell mobilization were studied on cycle 1. Growth factor-related toxicity, transfusions, and episodes of fever and neutropenia and infections were collected for cycles 1 to 4.

Results: Thirty-four patients (median age, 20 years; range 3.8-25.8) were enrolled, and 32 completed cycles 1 to 4. The median (range) duration of absolute neutrophil count of <500/mcL was 5.5 (3-8) days for pegfilgrastim and 6 (0-9) days for filgrastim (P = 0.76) after VDC, and 1.5 (0-4) days for pegfilgrastim and 3.75 (0-6.5) days for filgrastim (P = 0.11) after IE. More episodes of febrile neutropenia and documented infections occurred on the filgrastim arm. Serum pegfilgrastim concentrations were highly variable. Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults.

Conclusion: A single dose per cycle of pegfilgrastim was well tolerated and may be as effective as daily filgrastim based on the duration of severe neutropenia and number of episodes of febrile neutropenia and documented infections after dose-intensive treatment with VDC and IE.

PubMed Disclaimer

Figures

Fig 1
Fig 1
The number of days of severe neutropenia in patients treated with pegfilgrastim compared to patients treated with filgrastim during (A) cycles 1 and 2 of V3DC and (B) cycles 3 and 4 of IE. Symbols represents the average days of severe neutropenia during cycle 1 and 2 or 3 and 4 for each patient; the line is the median for each group.
Fig 1
Fig 1
The number of days of severe neutropenia in patients treated with pegfilgrastim compared to patients treated with filgrastim during (A) cycles 1 and 2 of V3DC and (B) cycles 3 and 4 of IE. Symbols represents the average days of severe neutropenia during cycle 1 and 2 or 3 and 4 for each patient; the line is the median for each group.
Fig 2
Fig 2
Absolute neutrophil counts (ANC) during cycles 1 and 2 of V3DC on the pegfilgrastim arm (A) and the filgrastim arm (B) and cycles 3 and 4 of IE on the pegfilgrastim arm (C) and the filgrastim arm (D) for all patients. Geometric mean serum G-CSF concentration for patients receiving pegfilgrastim is presented for cycle 1 in panel A.
Fig 2
Fig 2
Absolute neutrophil counts (ANC) during cycles 1 and 2 of V3DC on the pegfilgrastim arm (A) and the filgrastim arm (B) and cycles 3 and 4 of IE on the pegfilgrastim arm (C) and the filgrastim arm (D) for all patients. Geometric mean serum G-CSF concentration for patients receiving pegfilgrastim is presented for cycle 1 in panel A.
Fig 2
Fig 2
Absolute neutrophil counts (ANC) during cycles 1 and 2 of V3DC on the pegfilgrastim arm (A) and the filgrastim arm (B) and cycles 3 and 4 of IE on the pegfilgrastim arm (C) and the filgrastim arm (D) for all patients. Geometric mean serum G-CSF concentration for patients receiving pegfilgrastim is presented for cycle 1 in panel A.
Fig 2
Fig 2
Absolute neutrophil counts (ANC) during cycles 1 and 2 of V3DC on the pegfilgrastim arm (A) and the filgrastim arm (B) and cycles 3 and 4 of IE on the pegfilgrastim arm (C) and the filgrastim arm (D) for all patients. Geometric mean serum G-CSF concentration for patients receiving pegfilgrastim is presented for cycle 1 in panel A.
See this image and copyright information in PMC

References

    1. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18(13):2522–8. - PubMed
    1. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacotherapy. 2003;23(8 Pt 2):9S–14S. - PubMed
    1. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta) Curr Pharm Des. 2004;10(11):1235–44. - PubMed
    1. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35. - PubMed
    1. Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–31. - PubMed

Publication types